Shattuck Labs (NASDAQ:STTK) PT Set at $2.00 by Leerink Partners

Shattuck Labs (NASDAQ:STTK) has been given a $2.00 target price by stock analysts at Leerink Partners in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target indicates a potential upside of 100.00% from the company’s previous close.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $1.00 on Thursday. The business’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.01. Shattuck Labs has a one year low of $0.69 and a one year high of $3.95. The company has a market capitalization of $47.90 million, a P/E ratio of -0.83 and a beta of 1.63.

Shattuck Labs (NASDAQ:STTK) last issued its earnings results on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. On average, equities analysts anticipate that Shattuck Labs will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Zacks Investment Management acquired a new position in shares of Shattuck Labs during the 4th quarter valued at about $25,000. Northern Trust Corp boosted its stake in Shattuck Labs by 9.2% during the 4th quarter. Northern Trust Corp now owns 353,616 shares of the company’s stock valued at $428,000 after purchasing an additional 29,870 shares during the period. AQR Capital Management LLC boosted its stake in Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Shattuck Labs during the 4th quarter valued at approximately $45,000. Finally, 683 Capital Management LLC boosted its stake in Shattuck Labs by 4.3% during the 2nd quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock valued at $867,000 after purchasing an additional 45,000 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.